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Background
• Suboptimal blood pressure is number one attributable risk for 
death globally1
• 31% of Australian adults have blood pressure >=140/90mmHg2
• Latest international evidence suggests a continued evidence-
treatment gap3
1   World Health Report 2002: Reducing risks, promoting healthy life. Geneva, 
Switzerland: World Health Organisation, 2002. http://who.int/whr/2002
2   Australian Institute of Health and Welfare. National Cardiovascular Disease 
Database. Cardiovascular disease risk factors. Available at: http: 
//www.aihw.gov.au/pls/cvd/cvd_risk.show_form(accessed Jun 2006) 
3   Kastarinen et al. Trends in hypertension care in eastern and south-western Finland 
during 1982-2002. J Hypertens 2006 (24); 829-836.
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Objectives
• To examine the evidence-treatment gap 
for hypertension at a population level
• To discuss implications for future direction 
of Quality Use of Medicines (QUM) 
strategies
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Methodology
• Electoral roll random sample from Limestone 
Coast (LC, 2004) and Corangamite Shire 
(CO, 2005), aged 25-74 years
• WHO MONICA Protocol 
– www.ktl.fi/monica
• Recommendations of the European Health Risk 
Monitoring (EHRM) Project
– www.ktl.fi/ehrm
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Greater Green Triangle Region
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Survey Sites (CO)
Camperdown 
Cobden 
Lismore 
Terang 
Timboon 
www.greaterhealth.org
Survey Sites (LC)
Mount Gambier
Naracoorte 
Millicent
Keith
Bordertown
Penola
Lucindale
Robe
Kingston 
Lucindale
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Analysis
• Data from 891/967 (92%) participants
– BP measurement and medication 
information required for inclusion
• Identifying hypertensive participants
– BP readings, includes normotensive 
participants taking BP medications
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Analysis
• Categorisation of Hypertension
– Heart Foundation Guidelines (140/90mmHg)
• Participant categories examined
– Aware (controlled/uncontrolled)
– Unaware
– Normotensive
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Overall Age-Adjusted Results
• 35.1% hypertensive
• 51.9% of hypertensives used medication
• 58.4% of medication-users lacked BP 
control
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Blood pressure categories
Normal; < 140 / 90 mmHg
Moderate or severe; 
systolic BP > 160 mmHg OR 
diastolic BP > 100 mmHg
*
* P for difference <0.05
*100%
Males                                    Females              
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Mild
Normal
< 140 / 90 mmHg
systolic BP > 160 
mmHg OR 
diastolic BP > 100 
mmHg
* P for difference <0.05
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Prevalence of Hypertension
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Awareness and Control of 
Hypertension
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Number of Medications used 
for Hypertension
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Use of Medications among those 
aware of hypertension
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Discussion
• Physical measurements, not self-reported
• More powerful sub-analyses desirable
• Distinct detection and treatment issues
www.greaterhealth.org
Conclusions
• Guidelines not sufficiently effective at a 
population level
• QUM strategies4 need surveillance
• Targeted campaigns should be considered
4   Department of Health and Ageing. The National Strategy for Quality 
Use of Medicines. Commonwealth of Australia (Canberra), 2002. 
http://www.health.gov.au/internet/wcms/publishing.nsf/Content/nmp-
pdf-natstrateng-cnt.htm/$FILE/natstrateng.pdf (accessed June 
2006).
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